

## Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: *TP63* is amplified in early carcinogenesis but down-regulated as disease progressed

Chueh-Chuan Yen, Yann-Jang Chen, Chin-Chen Pan, Kai-Hsi Lu, Paul Chih-Hsueh Chen, Jiun-Yi Hsia, Jung-Ta Chen, Yu-Chung Wu, Wen-Hu Hsu, Liang-Shun Wang, Min-Hsiung Huang, Biing-Shiung Huang, Cheng-Po Hu, Po-Min Chen, Chi-Hung Lin

Chueh-Chuan Yen, Po-Min Chen, Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, China

Yann-Jang Chen, Faculty of Life Science, National Yang-Ming University, Taipei, Taiwan, China

Chin-Chen Pan, Paul Chih-Hsueh Chen, Department of Pathology, National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan, China

Kai-Hsi Lu, Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan, China

Jiun-Yi Hsia, Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, China

Jung-Ta Chen, Department of Pathology, Taichung Veterans General Hospital, and Department of Pathology, Chung-Shan Medical University, Taichung, Taiwan, China

Yu-Chung Wu, Wen-Hu Hsu, Liang-Shun Wang, Min-Hsiung Huang, Biing-Shiung Huang, Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, China

Cheng-Po Hu, Institute of Microbiology and Immunology, National Yang-Ming University, and Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, China  
Chi-Hung Lin, Institute of Microbiology and Immunology, and Institute of Biophotonics, National Yang-Ming University, Taipei, Taiwan, China

Supported by the National Microarray and Gene Expression Analysis Core Facility of the National Research Program for Genomic Medicine at National Yang-Ming University (<http://www.ym.edu.tw/microarray>), and annual project Grant From National Science Council (Grant NO. NSC 92-2314-B-075-055), Taiwan, China

Correspondence to: Dr. Chi-Hung Lin, Institute of Microbiology and Immunology, National Yang-Ming University, NO. 155, Li-Non St., Section 2, Taipei 112, Taiwan, China. [linch@ym.edu.tw](mailto:linch@ym.edu.tw)  
Telephone: +886-2-28267219 Fax: +886-2-28212880

Received: 2004-09-29 Accepted: 2004-10-18

### Abstract

**AIM:** By using comparative genomic hybridization, gain of 3q was found in 45-86% cases of esophageal squamous cell carcinoma (EC-SCC). Chromosome 3q25.3-qter is the minimal common region with several oncogenes found within this region. However, amplification patterns of these genes in EC-SCC have never been reported. The possible association of copy number changes of these genes with pathologic characteristics is still not clear.

**METHODS:** Real-time quantitative PCR (Q-PCR) was performed to analyze the copy number changes of 13

candidate genes within this region in 60 primary tumors of EC-SCC, and possible association of copy number changes with pathologic characteristics was analyzed by statistics. Immunohistochemistry (IHC) study was also performed on another set of 111 primary tumors of EC-SCC to verify the association between *TP63* expression change and lymph node metastasis status.

**RESULTS:** The average copy numbers ( $\pm$ SE) per haploid genome of individual genes in 60 samples were (from centromere to telomere): *SSR3*: 4.19 ( $\pm$ 0.69); *CCNL1*: 5.24 ( $\pm$ 0.67); *SMC4L1*: 2.01 ( $\pm$ 0.16); *EVI1*: 2.02 ( $\pm$ 0.12); *hTERC*: 5.28 ( $\pm$ 0.54); *SKIL*: 2.71 ( $\pm$ 0.14); *EIF5A2*: 1.95 ( $\pm$ 0.12); *ECT2*: 9.18 ( $\pm$ 1.68); *PIK3CA*: 8.13 ( $\pm$ 1.17); *EIF4G1*: 1.07 ( $\pm$ 0.05); *SST*: 3.07 ( $\pm$ 0.25); *TP63*: 2.51 ( $\pm$ 0.22); *TFRC*: 2.42 ( $\pm$ 0.19). Four clusters of amplification were found: *SSR3* and *CCLN1* at 3q25.31; *hTERC* and *SKIL* at 3q26.2; *ECT2* and *PIK3CA* at 3q26.31-q26.32; and *SST*, *TP63* and *TFRC* at 3q27.3-q29. Patients with lymph node metastasis had significantly lower copy number of *TP63* in the primary tumor than those without lymph node metastasis. IHC study on tissue arrays also showed that patients with lymph node metastasis have significantly lower *TP63* staining score in the primary tumor than those without lymph node metastasis.

**CONCLUSION:** This study showed that different amplification patterns were seen among different genes within 3q25.3-qter in EC-SCC, and several novel candidate oncogenes (*SSR3*, *SMC4L1*, *ECT2*, and *SST*) were identified. *TP63* is amplified in early stage of EC-SCC carcinogenesis but down-regulated in advanced stage of disease.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

**Key words:** Chromosomal aberration; Comparative genomic hybridization; Esophageal neoplasm; Immunohistochemistry; Quantitative real-time PCR; Tissue array; Tumor protein 63

Yen CC, Chen YJ, Pan CC, Lu KH, Chen PCH, Hsia JY, Chen JT, Wu YC, Hsu WH, Wang LS, Huang MH, Huang BS, Hu CP, Chen PM, Lin CH. Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: *TP63* is amplified in early carcinogenesis but down-regulated as disease progressed. *World J Gastroenterol* 2005; 11(9): 1267-1272

<http://www.wjgnet.com/1007-9327/11/1267.asp>

## INTRODUCTION

Esophageal cancer (EC) is one of the most lethal cancers in the world<sup>[1]</sup> as well as in Taiwan (<http://www.doh.gov.tw/dohenglish/Upload/Statistics/S02/91110-eng.xls>). In most Asian countries, squamous cell carcinoma (EC-SCC) is the most frequent histological subtype of EC. By using modern molecular cytogenetic study such as comparative genomic hybridization (CGH)<sup>[2]</sup> and spectral karyotyping (SKY)<sup>[3]</sup>, several recurrent chromosomal aberrations of EC-SCC were identified. Among them, chromosome 3q is especially important, because 45-86% cases of EC-SCC were found to have amplification in this region, with minimal overlapping region over 3q25.3-qter<sup>[4-8]</sup>. Gain of chromosome 3q was also reported in many other tumors, such as cancer of the lung<sup>[9]</sup>, ovary<sup>[10]</sup>, and cervix<sup>[11,12]</sup>, and head and neck squamous cell carcinoma (HNSCC)<sup>[13,14]</sup>.

The size of 3q25.3-qter is about 40 MB, containing about 367 known genes within this region, not to mention the unknown ones. Several candidate oncogenes were located in this chromosomal region, such as cyclin L1 (*CCNL1*), at 3q25; human telomerase RNA component (*bTERC*), at 3q26; phosphoinositide-3-kinase, catalytic, alpha polypeptide (*PIK3CA*), at 3q26; Ski-like protein (*SKIL*), at 3q26; ecotropic viral integration site 1 (*EVI1*), at 3q26; eukaryotic translation initiation factor 5A2 (*EIF5A2*), at 3q26; eukaryotic translation initiation factor 4gamma1 (*EIF4G1*), at 3q27; tumor protein 63 (*TP63*), at 3q28; and transferrin receptor (*TFRC*), at 3q29 (GeneCards<sup>TM</sup>, <http://bioinformatics.weizmann.ac.il/cards/>). However, amplification patterns of these genes in EC-SCC have never been reported.

A recently introduced method, real-time quantitative PCR (Q-PCR), could be used to accurately evaluate copy numbers of genes with only minimal amounts of tumor materials with high-throughput capacity<sup>[15-17]</sup>. In previous study, the accuracy of assessing copy number changes by Q-PCR in comparison with fluorescence *in situ* hybridization (FISH) had been demonstrated<sup>[18]</sup>. In this study, Q-PCR was used to study the copy number changes of the afore mentioned nine candidate oncogenes, together with four genes [signal sequence receptor gamma (*SSR3*) at 3q25.31, structural maintenance of chromosomes 4-like 1 (*SMC4L1*) at 3q26.1, epithelial cell transforming sequence 2 oncogene (*ECT2*) at 3q26.31, and somatostatin (*SST*) at 3q27.3] that were not down-regulated in our preliminary expression profile study, within chromosome 3q25.3-qter region in 60 primary tumors of EC-SCC, and the possible associations of these changes with disease progression were analyzed. Immunohistochemistry (IHC) was also used to verify the association of expression change of *TP63* with lymph node metastasis status on another 111 cases of EC-SCC.

## MATERIALS AND METHODS

### Primary tumors and cell lines of EC-SCC

From 1995 to 1997, 60 ethic Chinese patients with EC-SCC were enrolled for Q-PCR study. All patients underwent primary surgical resection without neoadjuvant chemotherapy or radiotherapy. Only patients with written informed consent were included. Pathological evaluation of depth of tumor invasion, tumor differentiation and lymph node metastasis

were done by one of our pathologists (Jung-Ta Chen), and staging and grading of tumor were defined according to the Cancer Staging Manual (5th edition; American Joint Committee on Cancer). Portions of tumor from the paraffin-embedded primary tumor samples, of which at least 70% were tumor cells, were identified under the microscope by one of our pathologists (Jung-Ta Chen) and were cut out for study. The procedure of DNA extraction was modified from a previously described protocol<sup>[19]</sup>. CGH analysis of part of these patients had been previously reported<sup>[8]</sup>. DNA extracted from five volunteer donor lymphocytes was used as control. EC-SCC cell lines CE 48T/VGH, CE 81T/VGH, TE6 and TE9, which have been previously characterized by molecular cytogenetics<sup>[18]</sup>, were used to validate the accuracy of Q-PCR.

### Fluorescence in situ hybridization (FISH)

FISH was performed using methods as previously suggested<sup>[20]</sup>. The search for FISH probes covering the 13 genes was done by browsing Ensembl Genome Browser <http://www.ensembl.org/> and UCSC Genome Browser <http://genome.ucsc.edu> for candidate bacterial artificial chromosome (BAC) clones. The resulting clones were then obtained from RPCI-11 BAC library (Table 1)<sup>[21]</sup>. Their identities were verified by FISH-mapping onto normal lymphocyte metaphases. For each cell line, FISH signals were counted in 10 metaphases, and FISH signals per haploid genome were calculated by using average FISH signals per cell  $\times 23$  / average number of chromosomes per cell<sup>[18]</sup>.

### Real-time quantitative PCR (Q-PCR)

All primers were designed with Primer Express 3.0 software (Applied Biosystems Foster City, CA) using default parameters, with modified minimum amplicon length requirements (85 bp). An additional requirement consisted of a maximum GC content of 40% for the five last 3' end nucleotides. The sequences of the primers are listed in Table 1. PCR reactions were performed as previously described<sup>[18]</sup>. DNA content was normalized to that of long interspersed elements (*LINE1*), a repetitive element for which copy numbers per haploid genome are similar both in normal or neoplastic cells<sup>[17]</sup>. Copy number changes per haploid genome were calculated by using the formula  $2^{(Nt-Nline)/(Tt-Tline)}$ , where Nt is the threshold cycle number observed for an experimental primer in the normal DNA sample, Nline is the threshold cycle number observed for a *LINE1* primer in the normal DNA sample, and Tt and Tline are the threshold cycle numbers observed for the experimental primer and *LINE1* primer in test DNA sample, respectively<sup>[17]</sup>. For normal cell the copy number of a gene per haploid genome should be one. PCR for each primer set were performed in triplicate, and calculated copy number changes per haploid genome were averaged.

### Construction of tissue arrays

Tissue arrays of another 120 EC-SCC tumor samples were constructed using method as previously described<sup>[22]</sup>. Briefly, the H&E-stained slides of selected tumor samples were examined under a light microscope. The areas of interest were circled with a color pen, and a 16-gauge bone marrow

**Table 1** Covering BAC clones and position of 13 genes and sequence of Q-PCR primers of *LINE1* and 13 genes over 3q25.3-qter

Genes	BAC clones	Position	Forward primer	Reverse primer
<i>LINE1</i>	-	-	CCGCTCAACTACATGGAACTG	GCGTCCCAGAGATTCTGGTATG
<i>SSR3</i>	304C15	3q25.31	GCCCAGGCATATGAGAGTTGTC	CCAACATGGCAGGGTCAAGT
<i>CCNL1</i>	6F2	3q25.31	TCATGGCAGTCAACCAACAT	CCATGTGAAGGGCTTTTGGGA
<i>SMC4L1</i>	227J5	3q26.1	GGCAAAGTCTTAAGCAAGGTTGT	TCAACTGGCAAGCTAAGTGGA
<i>EV11</i>	141C22	3q26.2	CATGCATGCTGATTGCAGAAC	CCACCTGCCGAAAAATGGT
<i>hTERC</i>	40O08	3q26.2	CGTAGGCGCCGIGCTTT	TTTTCCGCCCGCTGAA
<i>SKIL</i>	543D10	3q26.2	GCTCGGCATTCCCAAGAAA	CCCCTTCCAACACAGCTGAGT
<i>EIF5A2</i>	110O7	3q26.2	GGCTTCCAGCACTTACCCTATG	GACCATGCTTCCAGTTTGG
<i>ECT2</i>	453J16	3q26.31	CCTAACAGCAATCGCAAACG	CTGTCTCTTTGAAAGCTGAGCAA
<i>PIK3CA</i>	245C23	3q26.32	GGAGGATGCCCAATTTGATG	AACAGTCCATGGCAGTTGAGA
<i>EIF4G1</i>	481O2	3q27.1	CCGGTTCAGAAATCTGAGTTTT	GATTCGGAGGGGCAAGCTG
<i>SST</i>	211G3	3q27.3	GATGCCCTGGAACCTGAAGA	GCCGGTTTIGAGTTAGCAGAT
<i>TP63</i>	313I6	3q28	CCTCGTCCACCAGTCCCTAT	GGAAGGACACGTCGAAAACCTG
<i>TFRC</i>	313F11	3q29	CAAAGTGGCAGCAGCAGCTG	GCTCTAGAATGAACGGTGAAG

*LINE1*: long interspersed elements; *SSR3*: signal sequence receptor gamma; *CCNL1*: cyclin L1; *SMC4L1*: structural maintenance of chromosomes 4-like 1; *EV11*: ecotropic viral integration site 1; *hTERC*: human telomerase RNA component; *SKIL*: Ski-like protein; *EIF5A2*: eukaryotic translation initiation factor 5A2; *ECT2*: epithelial cell transforming sequence 2 oncogene; *PIK3CA*: phosphoinositide-3-kinase, catalytic, alpha polypeptide; *EIF4G1*: eukaryotic translation initiation factor 4gamma1; *SST*: somatostatin; *TP63*: tumor protein 63; *TFRC*: transferrin receptor. BAC clones, clones of bacterial artificial chromosomes covering the genes obtained from RPCI-11 library.

biopsy trephine apparatus was used to punch at the circled areas, extracting a tissue cylinder with 2.0 mm diameter. At least three cylindrical core biopsies were taken from different sites of each tumor. About 40 cylinders (8×5) were carefully transferred with forceps to a recipient metal paraffin block box. The recipient box was then covered with a plastic cassette and then liquid wax was gently poured into the box until it was full. The box was then put on a hot plate for 1 min to homogenize the wax, after which the box was removed from the hot plate and cooled to room temperature slowly. Four-micrometer sections were cut and mounted on silane-coated slides.


### Immunohistochemistry (IHC) for *TP63*

Immunostaining for *TP63* was performed on tissue array slides using a mouse anti-human *TP63* monoclonal antibody clone: 7JUL (1:30; Novocastra, New Castle Upon Tyne, UK), which recognized all *TP63* isoforms, and high temperature antigen unmasking technique (autoclave in pH 8.0 EDTA buffer) as previously described<sup>[23]</sup>. The bound antibodies were detected using the DAKO Envision system. Positive control (non-neoplastic tonsil tissue) and negative control (replacement of primary antibody by PBS) were


included. The slides were independently reviewed by two of the authors (Chin-Chen Pan, Paul Chih-Hsueh Chen) who were blinded to the clinicopathologic data. *TP63* immunoreactivity was semi-quantified using a combined intensity and percentage of positive scoring method. Intense nuclear staining was scored as 2, weak as 1, and negative as 0 (Figure 1)<sup>[24]</sup>. The percentage of cells with each intensity score was estimated. A *TP63* staining score was defined as the sum of the percentage of positive cells with each intensity level multiplied by the intensity score [e.g., a case with 30% intense staining and 40% weak staining would be scored as 100 (30×2+40×1)]<sup>[24]</sup>.

### Statistical analysis


Statistical comparisons were performed using SPSS 12.0 software. Pearson coefficient of correlation was used to determine the correlation between the copy number changes assessed by FISH and Q-PCR. Student's *t*-test was used to test the association between the results of Q-PCR or the *TP63* staining score and lymph node metastasis or differentiation status. Kruskal-Wallis test was used to test the association between the results of Q-PCR or the *TP63* staining score and primary tumor extent.



**Figure 1** Immunoreactivity for *TP63*. A: Intense nuclear *TP63* staining; B: Weak nuclear *TP63* staining; C: Negative staining. (Original magnification: ×400).



**Figure 2** Comparison of copy numbers assessed by FISH (striped bar) and Q-PCR ( $\pm$ SD) (hollow bar) of 13 genes in 4 EC-SCC cell lines [CE 48T/VGH (pink), CE 81T/VGH (yellow), TE6 (green), TE9 (blue)]. Pearson coefficients of correlation for comparing FISH and Q-PCR of 13 genes in 4 cell lines were all  $>0.9$ .



**Figure 3** Average copy number changes (indicated by the circles with number listed beside them; crossbar represented  $2 \times$  standard error) of 13 genes in association of their relative position on chromosome 3q. Four clusters of amplifications could be found: *SSR3* and *CCLN1* at 3q25.31; *hTERC* and *SKIL* at 3q26.2; *ECT2* and *PIK3CA* at 3q26.31-q26.32; and *SST*, *TP63* and *TFRC* at 3q27.3-q29.


## RESULTS

### Evaluation of Q-PCR accuracy


The accuracy of the assay was tested on 4 EC-SCC cell lines. In Figure 2, copy number changes of 13 genes on these 4 EC-SCC cell lines, assessed by both FISH and Q-PCR, were quite compatible. The Pearson coefficients of correlation for comparing FISH and Q-PCR of 13 genes in 4 cell lines were all  $>0.9$ .

### Assessment of copy number changes of candidate genes in primary tumors by Q-PCR

Copy number changes of 13 candidate genes were assessed by Q-PCR in 60 primary EC-SCC tumors. The average copy numbers ( $\pm$ SE) per haploid genome of individual genes in 60 samples were (from centromere to telomere): *SSR3*: 4.19 ( $\pm 0.69$ ); *CCN1*: 5.24 ( $\pm 0.67$ ); *SMC4L1*: 2.01 ( $\pm 0.16$ ); *EVI1*: 2.02 ( $\pm 0.12$ ); *hTERC*: 5.28 ( $\pm 0.54$ ); *SKIL*: 2.71 ( $\pm 0.14$ ); *EIF5A2*: 1.95 ( $\pm 0.12$ ); *ECT2*: 9.18 ( $\pm 1.68$ ); *PIK3CA*: 8.13 ( $\pm 1.17$ ); *EIF4G1*: 1.07 ( $\pm 0.05$ ); *SST*: 3.07 ( $\pm 0.25$ ); *TP63*: 2.51 ( $\pm 0.22$ ); *TFRC*: 2.42 ( $\pm 0.19$ ). Four clusters of amplification could be found: *SSR3* and *CCLN1* at 3q25.31; *hTERC* and *SKIL* at 3q26.2; *ECT2* and *PIK3CA* at 3q26.31-q26.32;



**Figure 4** In Q-PCR analysis of 60 EC-SCC tumors, patients with lymph node metastasis [LN (+)] have significantly lower copy number of *TP63* in the primary tumor than those without lymph node metastasis [LN (-)] (2.05 vs 3.08;  $P = 0.017$ ).



**Figure 5** In IHC study of 111 EC-SCC tumors, patients with lymph node metastasis [LN (+)] have significantly lower *TP63* staining score in the primary tumor than those without lymph node metastasis [LN (-)] (51.03 vs 79.62;  $P = 0.034$ ).

and *SST*, *TP63* and *TFRC* at 3q27.3-q29 (Figure 3).

### Association of copy number changes of candidate genes in primary tumors with disease staging or differentiation

The association between copy number changes of 13 genes and primary tumor extent, lymph node metastasis or tumor differentiation was analyzed. Patients with lymph node metastasis have significantly lower copy number of *TP63* in the primary tumor than those without lymph node metastasis (2.05 vs 3.08;  $P = 0.017$ ) (Figure 4). There were no significant association between copy number changes of the other 12 genes and lymph node metastasis. Also the copy number changes of all 13 genes had no statistical association with either primary tumor extent or tumor differentiation.

### Association of TP63 staining score in primary tumors with disease staging or differentiation

Immunostaining of *TP63* could be evaluated in 111 cases. The association between *TP63* staining score and primary tumor extent, lymph node metastasis or tumor differentiation was analyzed. As in the study of Q-PCR, patients with lymph node metastasis have significantly lower *TP63* staining score in the primary tumor than those without lymph node metastasis (51.03 vs 79.62;  $P = 0.034$ ) (Figure 5). There was no statistical association between *TP63* staining score and either primary tumor extent or tumor differentiation.

## DISCUSSION

In this study, the pattern of copy number changes of 13 potential target genes located on 3q25.3-qter in EC-SCC and the association of these changes with disease progression were analyzed. In general, all genes except *FIE4G1* had increased copy number. However, four clusters of genes with higher amplification were found: *SSR3* and *CCNL1* at 3q25.31; *bTERC* and *SKIL* at 3q26.2; *ECT2* and *PIK3CA* at 3q26.31-q26.32; and *SST*, *TP63* and *TFRC* at 3q27.3-q29, with highest peaks over *ECT2* and *PIK3CA* (Figure 3). In previous study, it was demonstrated that copy number of *PIK3CA* was significantly higher than that of *TP63* in EC-SCC<sup>[18]</sup>. Therefore, in EC-SCC, 3q26.31-q26.32 might be the most amplified area within this region.

*CCNL1*<sup>[25]</sup>, *bTERC*<sup>[26-28]</sup>, *SKIL*<sup>[29]</sup>, *PIK3CA*<sup>[30-32]</sup>, *TP63*<sup>[33-37]</sup> and *TFRC*<sup>[38]</sup> were reported as potential oncogenes in different diseases. However, *SSR3*, *SMC4L1*, *ECT2* and *SST* have never been previously identified as oncogenes. *SSR3* is one of the 4 members of translocon-associated protein (TRAP) over endoplasmic reticulum (ER) membrane. TRAP is responsible for the passage of peptide through ER membrane<sup>[39]</sup>. *SMC4L1* is one of the members of structural maintenance of chromosomes (SMC) proteins. The eukaryotic SMC proteins could form heterodimers, which may be involved in chromosome condensation, sister chromatid cohesion, and DNA recombination<sup>[40]</sup>. *ECT2* was identified as an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis<sup>[41]</sup>. Recent studies have showed that N-terminal truncation of *ECT2* may render it as an oncogenic protein, which may cause malignant transformation of cell<sup>[42]</sup>. *SST* (somatostatin) and its analogues have been used in the treatment of endocrine tumor. Whether these genes play roles in carcinogenesis of EC-SCC deserve further investigation.

It is very interesting to find that the copy number changes as well as expression of *TP63* decrease in more advanced stage of disease in EC-SCC. Heselmeyer *et al* reported that gain of chromosome 3q could be found in the early dysplasia lesion as well as in the invasive carcinoma of cervical cancer, but at reduced frequency in advanced stage of disease<sup>[11,12]</sup>. However, this phenomenon has never been reported in EC-SCC.

*TP63* gene, one of *TP53* gene family, is a well-known oncogene within this region. Overexpression of *TP63* was found in most squamous cell carcinoma<sup>[33-37]</sup>. In a IHC study of EC-SCC, *TP63* protein was found highly expressed in carcinoma (50/51), dysplasia (10/11), and even in histologically normal epithelia of esophagus adjacent to the cancerous tissues (45/47)<sup>[35]</sup>. On the contrary, in the study of *TP63* expression in urothelial carcinoma, Koga *et al* reported that lower *TP63* expression was significantly associated with higher Tumor-Node- Metastasis (TNM) stage ( $P = 0.0004$ ) and lymph-node metastasis ( $P = 0.013$ ). It was found that cancer cells with lower *TP63* staining had higher chance of lower membranous  $\beta$ -catenin expression, which plays a role in cell-cell adherent junctions, and cancer invasion and metastasis could be promoted by reduced membranous  $\beta$ -catenin expression<sup>[24]</sup>. In a similar study of upper urinary tract urothelial carcinoma, Zigeuner *et al* found that decreased *TP63* immunoreactivity was significantly associated

with advanced tumor stages and poor prognosis. They also found that cases with decreased *TP63* immunoreactivity had higher chance of *TP53* overexpression in comparison with cases with normal *TP63* immunoreactivity.

By combining results of this study with other reports, it is very likely that amplification of genes located on 3q25.3-qter may occur in quite early stage in the carcinogenesis of EC-SCC. But some of the genes, such as *TP63*, may be down-regulated as disease progressed. One possible explanation is that the alterations of genes are no longer necessary for maintenance of cancer cells survival. The other possibility is that down-regulation of these genes may accompany alterations of other genes (such as  $\beta$ -catenin or *TP53*), which may render cancer cell more invasive or malignant.

In conclusion, this study demonstrated different amplification patterns of different genes within 3q25.3-qter in EC-SCC, with highest amplification over 3q26.31-q26.32. *SSR3*, *SMC4L1*, *ECT2* and *SST* were identified as novel candidate oncogenes within this region. *TP63* is amplified in early stage of EC-SCC carcinogenesis but down-regulated in advanced stage of disease.

## ACKNOWLEDGEMENTS

The authors gratefully acknowledge the technical support from National Yang-Ming University Genome Research Center (<http://genome.ym.edu.tw/>).

## REFERENCES

- 1 **Wobst A**, Audisio RA, Colleoni M, Geraghty JG. Esophageal cancer treatment: studies, strategies and facts. *Ann Oncol* 1998; **9**: 951-962
- 2 **Kallioniemi A**, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. *Science* 1992; **258**: 818-821
- 3 **Schrock E**, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. Multicolor spectral karyotyping of human chromosomes. *Science* 1996; **273**: 494-497
- 4 **Du Plessis L**, Dietzsch E, Van Gele M, Van Roy N, Van Helden P, Parker MI, Mugwanya DK, De Groot M, Marx MP, Kotze MJ, Speleman F. Mapping of novel regions of DNA gain and loss by comparative genomic hybridization in esophageal carcinoma in the Black and Colored populations of South Africa. *Cancer Res* 1999; **59**: 1877-1883
- 5 **Pack SD**, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, Park WS, Pham T, Ault DO, Glaser M, Liotta L, Detera-Wadleigh SD, Wadleigh RG. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. *Genes Chromosomes Cancer* 1999; **25**: 160-168
- 6 **Tada K**, Oka M, Tangoku A, Hayashi H, Oga A, Sasaki K. Gains of 8q23-qter and 20q and loss of 11q22-qter in esophageal squamous cell carcinoma associated with lymph node metastasis. *Cancer* 2000; **88**: 268-273
- 7 **Ueno T**, Tangoku A, Yoshino S, Abe T, Toshimitsu H, Furuya T, Kawauchi S, Oga A, Oka M, Sasaki K. Gain of 5p15 detected by comparative genomic hybridization as an independent marker of poor prognosis in patients with esophageal squamous cell carcinoma. *Clin Cancer Res* 2002; **8**: 526-533
- 8 **Yen CC**, Chen YJ, Chen JT, Hsia JY, Chen PM, Liu JH, Fan FS, Chiou TJ, Wang WS, Lin CH. Comparative genomic hybridization of esophageal squamous cell carcinoma: correlations

- between chromosomal aberrations and disease progression/prognosis. *Cancer* 2001; **92**: 2769-2777
- 9 **Lu YJ**, Dong XY, Shipley J, Zhang RG, Cheng SJ. Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. *Lung Cancer* 1999; **23**: 61-66
- 10 **Arnold N**, Hagele L, Walz L, Schempp W, Pfisterer J, Bauknecht T, Kiechle M. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. *Genes Chromosomes Cancer* 1996; **16**: 46-54
- 11 **Heselmeyer K**, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, Auer G, Ried T. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. *Genes Chromosomes Cancer* 1997; **19**: 233-240
- 12 **Heselmeyer K**, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G, Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. *Proc Natl Acad Sci USA* 1996; **93**: 479-484
- 13 **Fang Y**, Guan X, Guo Y, Sham J, Deng M, Liang Q, Li H, Zhang H, Zhou H, Trent J. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. *Genes Chromosomes Cancer* 2001; **30**: 254-260
- 14 **Gain of DNA copy number on chromosomes 3q26-qter and 5p14-pter is a frequent finding in head and neck squamous cell carcinomas.** *Int J Mol Med* 1998; **2**: 173-179
- 15 **Bieche I**, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. *Int J Cancer* 1998; **78**: 661-666
- 16 **De Preter K**, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, Francotte N, Board J, Pearson AD, De Paepe A, Van Roy N, Vandesompele J. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. *Mod Pathol* 2002; **15**: 159-166
- 17 **Wang TL**, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, Velculescu VE. Digital karyotyping. *Proc Natl Acad Sci USA* 2002; **99**: 16156-16161
- 18 **Yen CC**, Chen YJ, Lu KH, Hsia JY, Chen JT, Hu CP, Chen PM, Liu JH, Chiou TJ, Wang WS, Yang MH, Chao TC, Lin CH. Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. *Int J Oncol* 2003; **23**: 871-881
- 19 **Isola J**, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. *Am J Pathol* 1994; **145**: 1301-1308
- 20 **Pinkel D**, Landegent J, Collins C, Fuscoe J, Seagraves R, Lucas J, Gray J. Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. *Proc Natl Acad Sci USA* 1988; **85**: 9138-9142
- 21 **Osoegawa K**, Mammoser AG, Wu C, Frengen E, Zeng C, Catanese JJ, de Jong PJ. A bacterial artificial chromosome library for sequencing the complete human genome. *Genome Res* 2001; **11**: 483-496
- 22 **Pan CC**, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. *J Pathol* 2004; **202**: 375-381
- 23 **Pan CC**, Chen PC, Chou TY, Chiang H. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. *Hum Pathol* 2003; **34**: 1155-1162
- 24 **Koga F**, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. *Clin Cancer Res* 2003; **9**: 5501-5507
- 25 **Redon R**, Hussenet T, Bour G, Caulee K, Jost B, Muller D, Abecassis J, du Manoir S. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. *Cancer Res* 2002; **62**: 6211-6217
- 26 **Soder AI**, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. *Oncogene* 1997; **14**: 1013-1021
- 27 **Hiyama T**, Yokozaki H, Kitadai Y, Haruma K, Yasui W, Kajiyama G, Tahara E. Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. *Virchows Arch* 1999; **434**: 483-487
- 28 **Yokoi S**, Yasui K, Iizasa T, Imoto I, Fujisawa T, Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. *Clin Cancer Res* 2003; **9**: 4705-4713
- 29 **Imoto I**, Pimkhaokham A, Fukuda Y, Yang ZQ, Shimada Y, Nomura N, Hirai H, Imamura M, Inazawa J. SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. *Biochem Biophys Res Commun* 2001; **286**: 559-565
- 30 **Redon R**, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. *Cancer Res* 2001; **61**: 4122-4129
- 31 **Ma YY**, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. PIK3CA as an oncogene in cervical cancer. *Oncogene* 2000; **19**: 2739-2744
- 32 **Woenckhaus J**, Steger K, Werner E, Fenic I, Gamedinger U, Dreyer T, Stahl U. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. *J Pathol* 2002; **198**: 335-342
- 33 **Hibi K**, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. *Proc Natl Acad Sci USA* 2000; **97**: 5462-5467
- 34 **Hibi K**, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nakao A. AIS overexpression in advanced esophageal cancer. *Clin Cancer Res* 2001; **7**: 469-472
- 35 **Hu H**, Xia SH, Li AD, Xu X, Cai Y, Han YL, Wei F, Chen BS, Huang XP, Han YS, Zhang JW, Zhang X, Wu M, Wang MR. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. *Int J Cancer* 2002; **102**: 580-583
- 36 **Glickman JN**, Yang A, Shahsafaee A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. *Hum Pathol* 2001; **32**: 1157-1165
- 37 **Wang TY**, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD, Crum CP. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. *Hum Pathol* 2001; **32**: 479-486
- 38 **Tanaka N**, Sugihara K, Odajima T, Mimura M, Kimijima Y, Ichinose S. Oral squamous cell carcinoma: electron microscopic and immunohistochemical characteristics. *Med Electron Microsc* 2002; **35**: 127-138
- 39 **Hartmann E**, Gorlich D, Kostka S, Otto A, Kraft R, Knespel S, Burger E, Rapoport TA, Prehn S. A tetrameric complex of membrane proteins in the endoplasmic reticulum. *Eur J Biochem* 1993; **214**: 375-381
- 40 **Strunnikov AV**, Jessberger R. Structural maintenance of chromosomes (SMC) proteins: conserved molecular properties for multiple biological functions. *Eur J Biochem* 1999; **263**: 6-13
- 41 **Tatsumoto T**, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. *J Cell Biol* 1999; **147**: 921-928
- 42 **Saito S**, Liu XF, Kamijo K, Raziuddin R, Tatsumoto T, Okamoto I, Chen X, Lee CC, Lorenzi MV, Ohara N, Miki T. Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. *J Biol Chem* 2004; **279**: 7169-7179